Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Biological Drugs in Guillain-Barre Syndrome: An Update Publisher Pubmed



Motamedgorji N1 ; Matin N2 ; Tabatabaie O3 ; Pavone P4 ; Romano C4 ; Falsaperla R4 ; Vitaliti G4
Authors
Show Affiliations
Authors Affiliations
  1. 1. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Neurology, Massachusetts General Hospital, Boston, MA, United States
  3. 3. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States
  4. 4. General Paediatrics Operative Unit, Policlinico-Vittorio Emanuele University Hospital, University of Catania, Catania, Italy

Source: Current Neuropharmacology Published:2017


Abstract

Background: Guillain-Barre Syndrome (GBS) is currently considered the most common global cause of acute flaccid paralysis. Currently, standard therapy for Guillain-Barre Syndrome includes intravenous immunoglobulin or plasma exchange. Despite medical advances regarding these treatments, many treated patients do not reach full recovery. Therefore several biological agents have attracted the attentions from researchers during the last decades, and various studies have investigated their role in Guillain-Barre Syndrome. Objective: The present study aims to address emerging biological approaches to GBS while considering their efficiency and safety in treating the disease. Materials and Methods: An extensive electronic literature search was conducted by two researchers from April 2016 to July 2016. Original articles, clinical trials, systematic reviews (with or without meta-analysis) and case reports were selected. Titles and abstracts of papers were screened by reviewers to determine whether they met the eligibility criteria, and full texts of the selected articles were retrieved. Results: Herein authors focused on the literature data concerning emerging biological therapeutic agents, namely anti-C5 monoclonal antibody (Eculizumab), anti-C1q monoclonal antibody, anti-T cell monoclonal antibody, anti-CD2 monoclonal antibody, anti L-selectin monoclonal antibody, anti-CD20 monoclonal antibody (Rituximab), anti-CD52 monoclonal antibody (Alemtuzumab) and cytokine targets. By far, none of these agents have been approved for the treatment of GBS by FDA. Conclusion: Literature findings represented in current review herald promising results for using these biological targets. Current review represents a summary of what is already in regards and what progress is required to improve the immunotherapeutic approach of treating GBS via future studies. © 2017 Bentham Science Publishers.
Related Docs
1. Autoimmunity and Cytokines in Guillain-Barre Syndrome Revisited: Review of Pathomechanisms With an Eye on Therapeutic Options, European Cytokine Network (2019)
2. Autoimmune Diseases, Clinical Immunology (2022)
3. Covid-19 As a Trigger of Guillain-Barre Syndrome: A Review of the Molecular Mechanism, Immunity# Inflammation and Disease (2023)
4. Cytomegalovirus Infection and Guillain-Barre Syndrome: The First Case-Control Study in Iran, Iranian Journal of Child Neurology (2021)
5. The Gut-Brain Axis: A New Pathogenic View of Neurologic Symptoms - Description of a Pediatric Case, Journal of Pediatric Neurosciences (2017)
6. Eculizumab in Kidney Diseases, Journal of Nephropharmacology (2024)
7. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following Covid-19: Molecular Mechanisms and Therapeutic Opportunities, Frontiers in Molecular Biosciences (2022)
8. Idiopathic Intracranial Hypertension in a Paediatric Population: A Retrospective Observational Study on Epidemiology, Symptoms and Treatment, Journal of Biological Regulators and Homeostatic Agents (2017)
Experts (# of related papers)
View all Related Experts
Nima Rezaei (2)
Shima Mahmoudi (1)